A carregar...

ICER, ISPOR AND QALYs: Tales of Imaginary Worlds

Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the lack of credibility in modeled claims for cost-effectiveness and associated recommendations for pricing by the Institute for Clinical and Economic Review (ICER). The principal objection to ICER r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Innov Pharm
Autor principal: Langley, Paul C
Formato: Artigo
Idioma:Inglês
Publicado em: University of Minnesota Libraries Publishing 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8051886/
https://ncbi.nlm.nih.gov/pubmed/34007578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.24926/iip.v10i4.2266
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!